Exosome formulation developed for choroidal neovascularisation therapy
An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
List view / Grid view
An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
A metabolic control pathway that regulates T follicular helper cells could enhance vaccine effectiveness, including those that protect against COVID-19.
In non-human primates, researchers have found that mesenchymal stem cells were effective at strengthening the immune response to HIV.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.